IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
Year: 2021
Type: article
Abstract: BACKGROUND: Pharmacological autophagy enhancement constitutes a preclinically validated strategy for preventing or treating most major age-associated diseases. Driven by this consideration, we performed a high-content/high-throughput screen on 65 000 distinct compounds on a robotized fluorescence microscopy platform to identify novel autophagy inducers. RESULTS: Here, we report the discovery of picropodophyllin (PPP) as a potent inducer of autophagic flux that acts on-target, as an inhibitor of the tyrosine kinase activity of the insulin-like growth factor-1 receptor (IGF1R). Thus, PPP lost its autophagy-stimulatory activity in cells engineered to lack IGF1R or to express a constitutively active AKT serine/threonine kinase 1 (AKT1) mutant. When administered to cancer-bearing mice, PPP improved the therapeutic efficacy of chemoimmunotherapy with a combination of immunogenic cytotoxicants and programmed cell death 1 (PDCD1, better known as PD-1) blockade. These PPP effects were lost when tumors were rendered PPP-insensitive or autophagy-incompetent. In combination with chemotherapy, PPP enhanced the infiltration of tumors by cytotoxic T lymphocytes, while reducing regulatory T cells. In human triple-negative breast cancer patients, the activating phosphorylation of IGF1R correlated with inhibited autophagy, an unfavorable local immune profile, and poor prognosis. CONCLUSION: Altogether, these results suggest that IGF1R may constitute a novel and druggable therapeutic target for the treatment of cancer in conjunction with chemoimmunotherapies.
Institutions: Inserm, Institut Universitaire de France, Université Paris Cité, Université Paris-Saclay, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, Renmin Hospital of Wuhan University, University of Graz, Nawi Graz, BioTechMed-Graz, Karolinska University Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Karolinska Institutet, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Suzhou Institute of Systems Medicine
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,804
Funders: Association pour la Recherche sur le Cancer, Seerave Foundation, European Commission, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Austrian Science Fund, Fondation pour la Recherche Médicale, Natural Science Foundation of Hubei Province, Conseil Régional, Île-de-France, Ligue Contre le Cancer, Labex, China Scholarship Council, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Université Paris-Saclay, Institut Gustave-Roussy, Karl-Franzens-Universität Graz, Bundesministerium für Bildung, Wissenschaft und Forschung, BioTechMed-Graz, High-end Foreign Experts Recruitment Plan of China
Awards: Next-generation phenotypic screening for oncological applications, G1725721203, Autophagic regulation of memory and brain longevity, G2114920166, Geroprotection By Synergistic Anti-Aging Interventions, Immuno-Oncology, G3385699963, Pro-autophagic polyphenols and polyamines for longevity, G3880385263, Causal epigenetic changes during aging and caloric restriction, G7263531341, Metabolic and Cardiovascular Disease, Mechanisms of spermidine mediated neuroprotection, Université de Paris, G8656799164, G98648609
OpenAlex ID: W3166418545
